TY - JOUR
T1 - Medication Adherence Following Acute Coronary Syndrome
T2 - Does One Size Fit All?
AU - Bernal, Daniel D.L.
AU - Bereznicki, Luke R.E.
AU - Chalmers, Leanne
AU - Castelino, Ronald L.
AU - Thompson, Angus
AU - Davidson, Patricia M.
AU - Peterson, Gregory M.
N1 - Publisher Copyright:
© 2015, Springer International Publishing Switzerland.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Guideline-based management of acute coronary syndrome (ACS) is well established, yet some may challenge that strict implementation of guideline recommendations can limit the individualization of therapy. The use of all recommended medications following ACS places a high burden of responsibility and cost on patients, particularly when these medications have not been previously prescribed. Without close attention to avoiding non-adherence to these medications, the full benefits of the guideline recommendations will not be realized in many patients. Using a case example, we discuss how the recognition of adherence barriers can be an effective and efficient process for identifying patients at risk of non-adherence following ACS. For those identified as at risk, the World Health Organization’s model of adherence barriers is explored as a potentially useful tool to assist with individualization of therapy and promotion of adherence.
AB - Guideline-based management of acute coronary syndrome (ACS) is well established, yet some may challenge that strict implementation of guideline recommendations can limit the individualization of therapy. The use of all recommended medications following ACS places a high burden of responsibility and cost on patients, particularly when these medications have not been previously prescribed. Without close attention to avoiding non-adherence to these medications, the full benefits of the guideline recommendations will not be realized in many patients. Using a case example, we discuss how the recognition of adherence barriers can be an effective and efficient process for identifying patients at risk of non-adherence following ACS. For those identified as at risk, the World Health Organization’s model of adherence barriers is explored as a potentially useful tool to assist with individualization of therapy and promotion of adherence.
UR - http://www.scopus.com/inward/record.url?scp=84956641755&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84956641755&partnerID=8YFLogxK
U2 - 10.1007/s40256-015-0149-9
DO - 10.1007/s40256-015-0149-9
M3 - Article
C2 - 26547866
AN - SCOPUS:84956641755
SN - 1175-3277
VL - 16
SP - 9
EP - 17
JO - American Journal of Cardiovascular Drugs
JF - American Journal of Cardiovascular Drugs
IS - 1
ER -